无症状绝经前妇女子宫内膜异位囊肿的输卵管卵巢切除术与监测:成本效果分析
本研究采用TreeAge Pro建立终身 horizon 的成本效果模型,纳入不要求生育的无症状子宫内膜异位囊肿绝经前患者,比较单侧输卵管卵巢切除术与超声监测(诊断后6-12周及之后每年)的策略。
要点
- 模型显示单侧输卵管卵巢切除术死亡0.28% vs 监测1.50%,卵巢癌0.42% vs 2.96%。
- 单侧输卵管卵巢切除术费用6403.43美元 vs 监测5381.39美元。
核心结论
- 作者认为,对于不要求生育的绝经前无症状子宫内膜异位囊肿患者,单侧输卵管卵巢切除术相比监测具有成本效果,为优选策略。
- 单侧输卵管卵巢切除术死亡更少(0.28% vs 1.50%)、卵巢癌更少(0.42% vs 2.96%),费用更高(6403.43美元 vs 5381.39美元)。
研究设计与样本
- 研究采用TreeAge Pro软件建立成本效果模型,时间范围为终身。
- 假设队列为拥有2个卵巢、不要求生育的绝经前患者,诊断为无症状子宫内膜异位囊肿后接受单侧输卵管卵巢切除术或监测(诊断后6-12周超声,之后每年)。
- 主要效果结局为死亡率,包括卵巢癌死亡、手术死亡及与手术绝经相关的全因死亡(±激素替代治疗)。
- 模型纳入手术并发症、隐匿性恶性肿瘤、对侧附件病变、手术绝经、激素替代治疗使用及卵巢癌发生的概率。
- 成本包括手术、并发症、超声监测、激素治疗及卵巢癌治疗,数据来自Medicare报销数据和已发表文献。
主要发现
- 单侧输卵管卵巢切除术死亡0.28% vs 监测1.50%。
- 单侧输卵管卵巢切除术卵巢癌0.42% vs 监测2.96%。
- 单侧输卵管卵巢切除术费用6403.43美元 vs 监测5381.39美元。
- 增量成本效果比为每避免1例死亡83,773.77美元、每避免1例卵巢癌40,237.80美元。
- 若选择单侧输卵管卵巢切除术而非监测,每40例患者可预防1例卵巢癌诊断,每82例患者可避免1例死亡。
关键数值与推荐
- 单侧输卵管卵巢切除术的增量成本效果比(每避免1例死亡83,773.77美元、每避免1例卵巢癌40,237.80美元)均远低于支付意愿阈值。
- 对所有输入变量进行单因素敏感性分析,未发现可改变结论的合理输入值。
临床怎么用
- 原文未据此给出推荐。
- 作者结论认为单侧输卵管卵巢切除术具有成本效果,为优选策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The lifetime risk of ovarian cancer is 1.9% among women with endometriosis compared with 1.3% among the general population. When an asymptomatic endometrioma is incidentally discovered on imaging, gynecologists must weigh the procedural complications and the potential for subsequent surgical menopause against future ovarian pathology or cancer. OBJECTIVE: We aimed to determine if performing unilateral salpingo-oophorectomy is a more cost-effective strategy for the prevention of death than surveillance for asymptomatic endometriomas. STUDY DESIGN: We created a cost-effectiveness model using TreeAge Pro (TreeAge Software Inc; Williamstown, MA) with a lifetime horizon. Our hypothetical cohort included premenopausal patients with 2 ovaries who did not desire fertility. Those diagnosed with asymptomatic endometrioma underwent either unilateral salpingo-oophorectomy or surveillance (ultrasound 6-12 weeks after diagnosis, then annually). Our primary effectiveness outcome was mortality, including death from ovarian cancer or surgery and all-cause mortality related to surgical menopause (± hormone replacement therapy) if the contralateral ovary is removed. We modeled the probabilities of surgical complications, occult malignancy, development of contralateral adnexal pathology, surgical menopause, use of hormone replacement therapy, and development of ovarian cancer. The costs included surgical procedures, complications, ultrasound surveillance, hormone therapy, and treatment of ovarian cancer, with information gathered from Medicare reimbursement data and published literature. Cost-effectiveness was determined using the incremental cost-effectiveness ratio of Δ costs / Δ deaths with a willingness-to-pay threshold of $11.6 million as the value of a statistical life. Multiple 1-way sensitivity analyses were performed to evaluate model robustness. RESULTS: Our model demonstrated that unilateral salpingo-oophorectomy is associated with improved outcomes compared with surveillance, with fewer deaths (0.28% vs 1.50%) and fewer cases of ovarian cancer (0.42% vs 2.96%). However, it costs more than sonographic surveillance at $6403.43 vs $5381.39 per case of incidental endometrioma. The incremental cost-effectiveness ratio showed that unilateral salpingo-oophorectomy costs $83,773.77 per death prevented and $40,237.80 per case of ovarian cancer prevented. As both values were well below the willingness-to-pay threshold, unilateral salpingo-oophorectomy is cost-effective and is the preferred strategy. If unilateral salpingo-oophorectomy were chosen over surveillance for premenopausal patients with incidental endometriomas, 1 diagnosis of ovarian cancer would be prevented in every 40 patients and 1 death averted in every 82 patients. We performed 1-way sensitivity analyses for all input variables and determined that there were no reasonable inputs that would alter our conclusions. CONCLUSION: Unilateral salpingo-oophorectomy is cost-effective and is the preferred strategy compared with surveillance for the management of incidental endometrioma in a premenopausal patient not desiring fertility. It incurs fewer deaths and fewer cases of ovarian cancer with costs below the national willingness-to-pay thresholds.
引用
- Orlando MS, Cadish LA, Shepherd JP, et al. Salpingo-oophorectomy or surveillance for ovarian endometrioma in asymptomatic premenopausal women: a cost-effectiveness analysis. Am J Obstet Gynecol. 2022. PMID: 35490792. doi:10.1016/j.ajog.2022.04.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。